STE Stock Recent News
STE LATEST HEADLINES
Barring Life Sciences and Dental, rest of STERIS (STE) operating segments report organic revenue growth in fiscal Q1.
Steris (STE) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.90 per share a year ago.
Medical equipment provider Steris on Tuesday raised its profit forecast for fiscal 2024 after strength in its core healthcare business boosted first-quarter results above Wall Street estimates.
DUBLIN, IRELAND, July 19, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2024 first quarter financial results at 9:00 a.m. ET on August 2, 2023. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.
Becton, Dickinson and Co. (BD) BDX, +0.96% said Tuesday it agreed to sell its surgical instrumentation platform to Steris for STE, +0.04% for $540 million, or about 3.2 times the annual revenue of $170 million for the units included in the deal. Steris said the deal is expected to add to its earnings after it closes by Sept.
Steris (STE) reported earnings 30 days ago. What's next for the stock?
Investors are optimistic about STERIS (STE) on strong segmental growth.
STERIS (STE) competes for pharmaceutical, research and industrial customers against several large companies that have robust product portfolios and global reach.
Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.